Physician

Mamoun E Bashir, MD

According to 2025 Medicare claims, Mamoun Bashir, MD (NPI: 1588851232) practices nephrology in the Odessa, TX market, with the plurality of this provider's patient population coming from Ector, TX. This provider's primary affiliated billing organization is MIDLAND KIDNEY CARE PLLC (NPI: 1881067973; TIN: 475493793) and primary practice location at 79761-5424. Bashir is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Bashir's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 404 traditional Medicare patients, billed 1,558 HCPCS/CPT codes, and received $194,431 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,805 prescription claims across 329 beneficiaries totaling $286,171 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 232 claims. Open Payments data shows 3 records totaling $69. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $120,184 and ending at $194,431. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $146,561 and ending at $286,171. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,324 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	314	1,725	$120,184
2016	308	1,483	$99,529
2017	361	1,802	$156,014
2018	485	2,354	$287,090
2019	436	2,220	$283,527
2020	348	1,202	$106,424
2021	441	1,535	$193,134
2022	396	1,521	$201,605
2023	432	1,541	$197,515
2024	404	1,558	$194,431

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	437	$146,561
2016	61	406	$97,054
2017	62	546	$218,498
2018	250	1,274	$180,577
2019	277	2,360	$450,351
2020	232	1,590	$214,415
2021	220	1,313	$125,133
2022	262	1,284	$148,447
2023	296	1,384	$189,244
2024	329	1,805	$286,171

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	22	$2,999
2016	N/R	16	$1,440
2017	N/R	11	$35
2018	N/R	93	$3,943
2019	74	529	$19,920
2020	65	559	$21,135
2021	23	332	$11,338
2022	N/R	249	$5,622
2023	N/R	229	$5,387
2024	N/R	232	$4,615

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	102	314	$264
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	81	106	$127
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	102	114	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	166	$89
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	96	299	$87

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	28	840	$107,825
Farxiga	Dapagliflozin Propanediol	64	2,280	$42,092
Auryxia	Ferric Citrate	13	390	$24,084
Sevelamer Carbonate	Sevelamer Carbonate	87	4,456	$19,653
Cinacalcet Hcl	Cinacalcet Hcl	22	900	$16,878

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	50	$1,222
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	63	$1,003
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	46	$847
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	37	$796
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$734

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$69	Aurinia Pharma U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mamoun E. Bashir, MD?

Tedicare shows public-source Medicare data for Mamoun E. Bashir, MD (NPI 1588851232), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mamoun E. Bashir, MD have ACO affiliation data?

Mamoun E. Bashir, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mamoun E. Bashir, MD?

Mamoun E. Bashir, MD is linked to MIDLAND KIDNEY CARE PLLC (billing NPI 1881067973) in the available physician profile data.

Does Mamoun E. Bashir, MD have Open Payments data?

Mamoun E. Bashir, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.